Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.6.0.2
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2016
USD ($)
ft²
Oct. 31, 2013
USD ($)
ft²
Dec. 31, 2016
USD ($)
Milestone
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Milestone
Dec. 31, 2013
shares
Alachua Facility [Member]            
Commitment And Contingencies [Line Items]            
Period of expired lease         3 years  
Period of lease         5 years  
Expiration period         Dec. 31, 2014  
Rent expense         $ 127,000  
Tampa Facility [Member]            
Commitment And Contingencies [Line Items]            
Period of lease 36 months 39 months        
Expiration period Feb. 29, 2020 Feb. 28, 2017        
Rent expense         $ 77,000  
Area of Office Space Leased | ft² 2,207 4,168        
Lease commencement date         Mar. 01, 2017  
Minimum [Member] | Alachua Facility [Member]            
Commitment And Contingencies [Line Items]            
Monthly lease payments     $ 9,641   $ 9,641  
Minimum [Member] | Tampa Facility [Member]            
Commitment And Contingencies [Line Items]            
Monthly lease payments $ 4,138 $ 6,426        
Maximum [Member] | Alachua Facility [Member]            
Commitment And Contingencies [Line Items]            
Monthly lease payments     $ 10,851   $ 10,851  
Maximum [Member] | Tampa Facility [Member]            
Commitment And Contingencies [Line Items]            
Monthly lease payments $ 4,392 $ 6,818        
UFRF License Agreement [Member]            
Commitment And Contingencies [Line Items]            
Company's obligation to pay from percentage of selling price of product         5.00%  
Company's obligation to pay from all revenue received from sublicenses         22.00%  
One-time commercialization fee monthly amount for calculation         $ 5,000  
Post-commercialization minimum royalty payments         50,000  
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount         $ 2,000,000  
One-time additional payment to UFRF as a percentage of total royalties due to UFRF         10.00%  
Minimum annual maintenance payment on license agreement         $ 10,000  
Quarterly maintenance payment to UFRF under installment plan         $ 2,500  
Termination notice period         90 days  
Texas A and M University License [Member]            
Commitment And Contingencies [Line Items]            
Company's obligation to pay from percentage of selling price of product         5.00%  
Post-commercialization minimum royalty payments         $ 100,000  
Termination notice period         90 days  
Initial payment to Texas A&M         $ 5,000  
Minimum consideration for the continuation of the license agreement         $ 15,000  
Number of milestones achieved | Milestone         0  
Texas A and M University License [Member] | Phase 1 Clinical Trial [Member]            
Commitment And Contingencies [Line Items]            
Date of milestone achievement under licensing agreement with Texas A&M         Jun. 01, 2019  
Milestone payment under licensing agreement         $ 50,000  
Texas A and M University License [Member] | Phase 2 Clinical Trial [Member]            
Commitment And Contingencies [Line Items]            
Date of milestone achievement under licensing agreement with Texas A&M         Jun. 01, 2022  
Milestone payment under licensing agreement         $ 100,000  
Texas A and M University License [Member] | Phase 3 Clinical Trial [Member]            
Commitment And Contingencies [Line Items]            
Date of milestone achievement under licensing agreement with Texas A&M         Jun. 01, 2025  
Milestone payment under licensing agreement         $ 150,000  
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]            
Commitment And Contingencies [Line Items]            
Date of milestone achievement under licensing agreement with Texas A&M         Jun. 01, 2026  
Milestone payment under licensing agreement         $ 400,000  
Texas A and M University License [Member] | Minimum [Member]            
Commitment And Contingencies [Line Items]            
Company's obligation to pay from percentage of selling price of product         2.00%  
Texas A and M University License [Member] | Scenario, Forecast [Member] | Amendment [Member]            
Commitment And Contingencies [Line Items]            
Minimum consideration for the continuation of the license agreement       $ 25,000    
Lantibiotic ECC [Member]            
Commitment And Contingencies [Line Items]            
Company's obligation to pay from percentage of selling price of product         25.00%  
Company's obligation to pay from all revenue received from sublicenses         50.00%  
Termination notice period         90 days  
Number of milestones achieved | Milestone     0      
Number of shares issued | shares           4,392,425
Maximum percentage of primary investment securities to investment of shares issued         10.00%  
Lantibiotic ECC [Member] | Investigational New Drug Application [Member]            
Commitment And Contingencies [Line Items]            
Percentage of number of shares of common stock equal to Base Shares         1.00%  
Lantibiotic ECC [Member] | Phase 2 Clinical Trial [Member]            
Commitment And Contingencies [Line Items]            
Percentage of number of shares of common stock equal to Base Shares         1.50%  
Lantibiotic ECC [Member] | New Drug Application or Biologics License Application [Member]            
Commitment And Contingencies [Line Items]            
Percentage of number of shares of common stock equal to Base Shares         2.50%  
Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]            
Commitment And Contingencies [Line Items]            
Percentage of number of shares of common stock equal to Base Shares         3.00%  
Lantibiotic ECC [Member] | Phase 3 Clinical Trial [Member]            
Commitment And Contingencies [Line Items]            
Percentage of number of shares of common stock equal to Base Shares         2.00%  
Oral Mucositis ECC [Member]            
Commitment And Contingencies [Line Items]            
Company's obligation to pay from percentage of selling price of product         12.00%  
Company's obligation to pay from all revenue received from sublicenses         50.00%  
Termination notice period         90 days  
Number of milestones achieved | Milestone         0  
Oral Mucositis ECC [Member] | Phase II Milestone Event [Member]            
Commitment And Contingencies [Line Items]            
Milestone payment under licensing agreement         $ 2,000,000  
Milestone measurement period         30 days  
Oral Mucositis ECC [Member] | Phase 2b/3 Milestone Event [Member]            
Commitment And Contingencies [Line Items]            
Milestone payment under licensing agreement         $ 5,000,000  
Milestone measurement period         30 days  
Oral Mucositis ECC [Member] | Regulatory Approval Application Milestone Event [Member]            
Commitment And Contingencies [Line Items]            
Milestone payment under licensing agreement         $ 5,000,000  
Milestone measurement period         30 days  
Oral Mucositis ECC [Member] | Approval Milestone Event [Member]            
Commitment And Contingencies [Line Items]            
Milestone payment under licensing agreement         $ 10,000,000  
Milestone measurement period         30 days  
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]            
Commitment And Contingencies [Line Items]            
Milestone payment under licensing agreement         $ 5,000,000  
Milestone measurement period         30 days  
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]            
Commitment And Contingencies [Line Items]            
Milestone payment under licensing agreement         $ 5,000,000  
Milestone measurement period         30 days  
Oral Mucositis ECC [Member] | Maximum [Member]            
Commitment And Contingencies [Line Items]            
Maturity of interest bearing promissory note         12 months